Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period
Lindsey Wang, Pamela B. Davis, David C. Kaelber, Nora D. Volkow, Rong Xu
Abstract
This study examines breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in March-August 2021, when the Delta variant predominated, among a general US cohort vaccinated with mRNA-1273 or BNT162b2.
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVirologyPeriod (music)Emergency medicineIntensive care medicineInternal medicineOutbreakInfectious disease (medical specialty)AcousticsPhysicsDiseaseSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies